Generation X, as the first do-it-yourself retirement generation, is falling behind. As the first generation funding ...

Chartwell Retirement Residences has appointed Gary Whitelaw as board chair as part of a broader board refresh. The Canadian operator of senior living communities said Monday that the move is part of a ...

Housing starts across Canada came in at a seasonally adjusted annualized rate of 254,058 units, a 9.4% increase from the month before, Canada Mortgage and Housing Corp. said Monday. Expectations were ...

Phillips 66 set a $2.4 billion capital budget for next year, comprising $1.1 billion for sustaining projects and $1.3 billion for growth projects. Chief Executive Mark Lashier said Monday that the ...

Quipt Home Medical has struck a deal to be acquired by Kingswood Capital Management and Forager Capital Management in a deal that values the provider of home-medical equipment at nearly $159 million.

Howard Marks has been writing investment memos for 35 years — and the one thing you’ll never read is him making the case for ...

The closures are projected to result in nearly 300 layoffs, as well as about $415 million in total pre-tax costs. A substantial portion of the costs are expected to be recognized during the fourth ...

Canopy Growth has agreed to acquire Quebec-based craft cannabis company MTL Cannabis in a deal worth about 125 million Canadian dollars ($90.8 million). The Canadian cannabis company said Monday that ...

Here are some of the stocks making notable moves in Monday's premarket action: iRobot shares slid 77% after [the Roomba maker ...

Talen on Monday said Terry Nutt, who joined the Houston power producer as chief financial officer in July 2023, will now serve as president, responsible for the daily operations of its business. Cole ...

Stiff person syndrome refers to a rare autoimmune neurological disorder that most commonly causes muscle stiffness and painful spasms that come and go and can worsen over time. There is currently no ...

Shares of Greenwich LifeSciences climbed after the company said its immunotherapy to prevent breast cancer recurrences showed a roughly 80% reduction in recurrence rate during a late-stage trial. The ...